共价布鲁顿酪氨酸激酶抑制剂（BTKi）治疗后复发/难治性套细胞淋巴瘤（r/r MCL）的未满足需求：系统文献综述与荟萃分析

To quantify the clinical unmet need of r/r MCL patients who progress on a covalent Bruton tyrosine kinase inhibitor (BTKi), we conducted a systematic review to identify studies that reported overall survival (OS), progression-free survival (PFS), or response outcomes of patients who received a chemo(immunotherapy) targeted agent standard therapy (STx) or brexucabtagene autoleucel (brexu-cel) in the post-BTKi setting. Twenty-six studies (23 observational; three trials) reporting outcomes from 2005 to 2022 were included.

Using two-stage frequentist meta-analyses, the estimated median PFS/OS for patients treated with an STx was 7. 6 months (95% CI: 3. 9-14. 6) and 9. 1 months (95% CI: 7. 3-11. 3), respectively. The estimated objective response rate (ORR) was 45% (95% CI: 34-57%). For patients treated with brexu-cel, the estimated median PFS/OS was 14. 9 months (95% CI: 10. 5-21. 0) and 32. 1 months (95% CI: 25. 2-41. 2), with a pooled ORR of 89% (95% CI: 86-91%).

Our findings highlight a significant unmet need for patients whose disease progresses on a covalent BTKi.